Clinical Trial Update: Trial Comparing Adjuvant Chemotherapy With Gemcitabine Versus mFolfirinox to Treat Resected Pancreatic Adenocarcinoma [Phase 3]

View source ↗

Summary

A Phase 3 trial comparing adjuvant chemotherapy with gemcitabine versus mFOLFIRINOX in resected pancreatic adenocarcinoma has completed enrollment.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Adenocarcinoma
• Pancreatic Ductal Adenocarcinoma

Drugs mentioned

• Gemcitabine (Gemcitabine)
• mFOLFIRINOX

Snippet

Sponsor: UNICANCER | Conditions: Pancreatic Adenocarcinoma (Ductal Adenocarcinoma) | Phase 3 | Status: COMPLETED